ecteinascidin 743 has been researched along with maraviroc in 2 studies
| Studies (ecteinascidin 743) | Trials (ecteinascidin 743) | Recent Studies (post-2010) (ecteinascidin 743) | Studies (maraviroc) | Trials (maraviroc) | Recent Studies (post-2010) (maraviroc) |
|---|---|---|---|---|---|
| 660 | 102 | 404 | 785 | 124 | 539 |
| Protein | Taxonomy | ecteinascidin 743 (IC50) | maraviroc (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 3.1 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0014 | |
| C-C chemokine receptor type 5 | Homo sapiens (human) | 0.0044 | |
| C-C chemokine receptor type 5 | Mus musculus (house mouse) | 0.0052 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aldinucci, D; Borghese, C; Casagrande, N | 2 |
1 review(s) available for ecteinascidin 743 and maraviroc
| Article | Year |
|---|---|
Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It.
Topics: Antibodies, Monoclonal, Humanized; Chemokines; Cytokines; Hodgkin Disease; Immunosuppressive Agents; Killer Cells, Natural; Maraviroc; Nivolumab; Prognosis; Receptors, CCR5; Reed-Sternberg Cells; T-Lymphocytes; Trabectedin; Tryptophan; Tumor Escape; Tumor Microenvironment; Zoledronic Acid | 2019 |
1 other study(ies) available for ecteinascidin 743 and maraviroc
| Article | Year |
|---|---|
In classical Hodgkin lymphoma the combination of the CCR5 antagonist maraviroc with trabectedin synergizes, enhances DNA damage and decreases three-dimensional tumor-stroma heterospheroid viability.
Topics: CCR5 Receptor Antagonists; DNA Damage; HIV Infections; Hodgkin Disease; Humans; Maraviroc; Receptors, CCR5; Trabectedin | 2022 |